Manufacturing capabilities and supply chain infrastructure are critical determinants of the intramuscular HPV vaccination market's ability to meet global elimination strategy demand and expand access to underserved populations. The production of HPV virus-like particle vaccines involves complex recombinant DNA technology, where L1 major capsid proteins are expressed in yeast or insect cell...